| Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States | Centers for Disease Control and Prevention |
|---|---|
| COVID-19 vaccine reactions: The difference between common and allergic reactions | Centers for Disease Control and Prevention |
mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-Cov-2 variants.
7| Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera | Centers for Disease Control and Prevention |
|---|---|
| FDA takes additional action in fight against COVID-19 by issuing emergency use authorization for second COVID-19 vaccine | Understanding viral vector COVID-19 vaccines |
When vaccine is limited, who should get vaccinated first? COVID-19 vaccines vs variants — Determining how much immunity is enough.
17| Information about COVID-19 vaccines for people with allergies | |
|---|---|
| What to expect after getting a COVID-19 vaccine | Centers for Disease Control and Prevention |
Vaccination considerations for persons with underlying medication conditions.
19